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Chromosomal abnormalities are implicated in a substantial number of human developmental syndromes, but for many such
disorders little is known about the causative genes. The recently described 1q41q42 microdeletion syndrome is characterized by
characteristic dysmorphic features, intellectual disability and brain morphological abnormalities, but the precise genetic basis for
these abnormalities remains unknown. Here, our detailed analysis of the genetic abnormalities of 1q41q42 microdeletion cases
identified TP53BP2, which encodes apoptosis-stimulating protein of p53 2 (ASPP2), as a candidate gene for brain abnormalities.
Consistent with this, Trp53bp2-deficient mice show dilation of lateral ventricles resembling the phenotype of 1q41q42
microdeletion patients. Trp53bp2 deficiency causes 100% neonatal lethality in the C57BL/6 background associated with a high
incidence of neural tube defects and a range of developmental abnormalities such as congenital heart defects, coloboma,
microphthalmia, urogenital and craniofacial abnormalities. Interestingly, abnormalities show a high degree of overlap with 1q41q42
microdeletion-associated abnormalities. These findings identify TP53BP2 as a strong candidate causative gene for central nervous
system (CNS) defects in 1q41q42 microdeletion syndrome, and open new avenues for investigation of the mechanisms underlying
CNS abnormalities.
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Chromosomal deletions that cause rare genetic disorders
usually affect more than one gene and cause multiple
phenotypic features. Identification of causative genes could
extend our understanding of molecular pathways that
are responsible for common diseases. Deletions in the
chromosomal 1q41−q44 region are significantly associated
with central nervous system (CNS) defects including
neural tube defects (NTDs), agenesis of corpus callosum,
microcephaly and hydrocephalus.1,2 In particular, small
interstitial deletions in the 1q41q42 region are implicated
in the 1q41q42 microdeletion syndrome with features of
severe developmental delay, intellectual disability, and brain
morphological abnormalities. A critical region comprising
the genes FBXO28, TP53BP2, CAPN2, and CAPN8 has
been proposed for the 1q41q42 microdeletion syndrome
based on the smallest region of overlap (SRO).3 FBXO28
(encoding the F-box only protein 28, a ubiquitin ligase) has
been proposed as a candidate gene responsible for seizures
and intellectual disability in microdeletion patients.4,5 How-
ever, the genes responsible for other phenotypes, in particular
the brain morphological abnormalities, of the syndrome are
unknown.
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TP53BP2, which is located at the boundary of 1q41 and
1q42, encodes the apoptosis-stimulating protein of p53 2
(ASPP2). It is also an ankyrin repeat, SH3 domain and proline-
rich containing protein (ASPP), originally identified as a
positive regulator of p53-mediated transcription of apoptotic
genes.6,7 In mice, ASPP2, encoded by Trp53bp2, is essential
for embryonic development:8,9 an ASPP2-null genotype in
mice is lethal prior to embryonic day E7 (ref. 8) and mice with
homozygous deletion of exon 3 exhibit loss of neuroepithelial
cell polarity and hydrocephalus.10 ASPP2 is involved in
regulating apoptosis through binding to p53 (and its sibling
proteins p63 and p73) via its C-terminus and in regulating cell
polarity through binding to the tight-junction protein PAR3 via
its N-terminus.10,11 Both p53 and PAR3 have been implicated
in NTDs,12–15 and the process of neural tube closure − which
involves convergent extension and apical constriction to enable
folding of a neuroepithelial sheet into the neural tube − involves
apicobasal polarity and apoptosis.16–18 Therefore, we hypothe-
sized that TP53BP2 might contribute to the developmental
abnormalities associated with 1q41q42 deletions. Through
examination of ASPP2 deficiency in mice and human patients,
we show that TP53BP2 is a strong candidate for being
a gene responsible for CNS defects and, potentially, other
1q4 deletion-associated phenotypes in humans.
Results
TP53BP2 deletions are associated with brain abnormal-
ities in 1q41q42 microdeletion syndrome. To identify the
gene(s) responsible for structural brain abnormalities in
1q41q42 microdeletion syndrome, we first established the
SRO in 1q41q42 microdeletion cases with structural
brain abnormalities. To date there are 31 reported 1q41q42
microdeletion cases and 26 of them have brain MRI/CT
recorded. Among the 26 cases with deletions in the 1q41q42
region for which neuroradiology reports and/or MRI scans
were available, 19 were from published reports and 7 are
newly identified cases (Supplementary Table 1).3,4,19–26 Of
these 26 cases, 19 patients showed detectable structural brain
abnormalities and their SRO (chr1:223 828 382−224 034 322;
hg19) contains the entire coding regions of CAPN2 and
TP53BP2, plus exons 1 and 2 of CAPN8 (Figure 1), whereas
in 4 of the remaining 7 cases without brain abnormalities the
TP53BP2 locus is not affected (Figures 1a and b).
CAPN2 and CAPN8 encode Ca2+-dependent proteases of
the calpain family.27 Mice deficient in the orthologous genes
Capn2, Capn8, and Trp53bp2 have been generated pre-
viously: Trp53bp2-deficient mice exhibit abnormalities in the
CNS,10 whereas Capn2-deficient and Capn8-deficient mice
show no abnormalities in the brain or nervous system.28–30
Publicly available data also show that TP53BP2 is expressed
more highly in the brain than all other examined tissues,
whereas CAPN2 is expressed at very low levels in the
brain compared to other tissues, and CAPN8 expression is
restricted to the stomach (Supplementary Figure 1a,
www.gtexportal.org)31 Additionally, TP53BP2 is most highly
expressed in the ventricular and subventricular zones in
the human embryonic brain throughout gestation, consistent
with it having a key role in embryonic brain development
(Supplementary Figure 1b, http://brainspan.org, http://human.
brain-map.org).32,33 We also found no deletions of TP53BP2
in publically available copy number data from two large
cohorts of healthy individuals (19 584 healthy individuals;34,35
or in an independent paediatric control group of 2026 (ref. 36)),
suggesting that TP53BP2 deletions may be pathogenic. In
contrast, two deletions, nsv520609 and nsv521758, spanning
multiple exons of CAPN2, were detected in the cohort of 2026
disease-free individuals.36 These observations suggest that
TP53BP2 is the strongest candidate for being the causative
gene responsible for brain morphological abnormalities
associated with 1q41q42 microdeletions.
Brain MRI reveals common ventricular abnormalities
among patients with TP53BP2 deletions. We compared
structural brain phenotypes among 1q41q42 microdeletion
patients with and without heterozygous TP53BP2 deletions.
Among the 22 TP53BP2 deletion cases, the most frequently
observed brain abnormality, seen in 16 out of 22 patients
(73%) with heterozygous TP53BP2 deletions, was dilation
of ventricles and/or ventricular dysmorphism, frequently
associated with hypoplasia or agenesis of corpus callosum
(Supplementary Table 2). All four 1q41q42 microdeletion
patients without TP53BP2 deletions showed normal ventri-
cles (Supplementary Table 2, Figure 1b). Corpus callosum
defects were observed in 10/22 (45%) of TP53BP2-deletion
patients (5 with agenesis and 5 with hypoplasia), but in none
of the patients without TP53BP2 mutations. Cerebellar
hypoplasia, encephalocele, hypomyelination, plagiocephaly,
holoprosencephaly, and malformations of sulcation were also
observed in some TP53BP2 deletion patients at a lower
frequency (Supplementary Table 2).
For the identified 26 cases of 1q41q42 microdeletion
patients, only 14 brain MRI scans were available to us and
12 of them had morphometry-compatible MRI scans (9 with
TP53BP2 deletion and 3 without) (Figure 2a). We used
probabilistic morphometry to quantify the lateral ventricle (LV)
volume of the 12 1q41q42 microdeletion patients (Figure 2b).
28 normal children’s brain MRIs from the NIH Paediatric MRI
Data Depository were used as controls (Figure 2b). As
expected, LV volume was significantly larger in the TP53BP2
deletion group (mean 33.4 ml) (Figure 2b) compared to control
group (mean 10.0 ml, S.D.= 4.5 ml) (Po0.001) and the LV
volumes of microdeletion patients without TP53BP2 deletions
were within normal range (Figure 2b).
We observed defects in the ventricles of cases with
TP53BP2 deletions but not in microdeletion cases without
TP53BP2 deletions. For example, in four cases with TP53BP2
deletions the bodies of the LVs appeared more parallel due
to hypoplasia of the corpus callosum (Figure 2c, Supple-
mentary Table 2: patients Case 4; Shaffer 3; Rosenfeld 8;
Rosenfeld 13). This is similar but more subtle than the
ventricular dysmorphism seen in association with agenesis
of corpus callosum. In three cases the LVs were asymmetric
with one side larger than the other (Figure 2c: patients
Shaffer 3; Rosenfeld 12 and Wat et al.26). These data show
that TP53BP2 deletions are associated with ventricular
abnormalities that are frequently accompanied by hypoplasia
of corpus callosum and/or cerebellum.
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ASPP2 deficiency in mice causes CNS abnormalities
with similar features to 1q41q42 microdeletion patients.
We used mice with deletion of Trp53bp2 exon 3 (Trp53bp2Δ3)
to examine how ASPP2 deficiency affects CNS development.
We showed previously that the Trp53bp2Δ3/Δ3 geno-
type results in severe developmental defects in a strongly
background-dependent manner: BALB/c Trp53bp2Δ3/Δ3 mice
are born at the expected rate but most develop severe
hydrocephalus before weaning, whereas only 30% of
mixed C57BL/6-129 Sv background (further referred to as
‘mixed’) Trp53bp2Δ3/Δ3 mice survive postnatally.10 On a pure
C57BL/6 (referred to as B6) background, which we
established by back-crossing over 10 generations, no
homozygous Trp53bp2Δ3/Δ3 mice survived after birth. The
surviving BALB/c Trp53bp2Δ3/Δ3 mice have a 100% incidence
of hop gait. Most severe cases of neonatal hydrocephalus
develop prior to birth and likely result from early defects in
brain development.
To provide direct evidence that ASPP2 deficiency causes
structural abnormalities in mouse embryonic brain, we used
micro-computed tomography (microCT) and high-resolution
episcopic microscopy (HREM) to examine Trp53bp2Δ3/Δ3
embryos. These methods allow reconstruction of three-
dimensional images as well as individual sections, showing
Figure 1 TP53BP2 is deleted in 1q41q42 microdeletion patients with brain abnormalities. (a) Genomic locations of 1q41q42 deletions from new and published patients. Red
indicates brain morphological abnormalities were reported for the patient, green indicates absence of reported brain abnormalities. The positions of the CAPN8, CAPN2,
TP53BP2, and FBXO28 genes are marked with black arrows; black line marks the position of TP53BP2. *FBXO28 is not contained in the smallest region of overlap (SRO) of
patient deletions with brain abnormalities. Panel generated using UCSC genome browser (http://genome.ucsc.edu), hg19 assembly. (b) The proportions of cases with and without
TP53BP2 deletion with and without brain abnormalities. (c) Focus on the SRO of patient deletions with brain morphological abnormalities. Patients with abnormal ventricles are
marked in dark purple
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the morphology of anatomical defects.37 At embryonic
stages E13.5 and E14.5, ~ 50% of Trp53bp2Δ3/Δ3 BALB/c
embryos exhibited enlargement of brain ventricles (Figure 3a).
Subcranial and intraventricular haemorrhages were also
visible by naked eye and micro-CT in 50% of Trp53bp2Δ3/Δ3
BALB/c embryos (Figure 3a, Supplementary Figures 3a
and b). Brains of virtually all Trp53bp2Δ3/Δ3 embryos examined
by HREM had absent or severely hypoplastic pineal gland
(Figure 3b). The spinal canal of all Trp53bp2Δ3/Δ3 embryoswas
abnormal with stenosis (Supplementary Figure 3c), the
presence of blood (Supplementary Figure 3d) or small
cyst-like structures in the caudal part of the neural tube
(Supplementary Figure 3e). All Trp53bp2Δ3/Δ3 embryos
examined had abnormalities in the cerebrospinal fluid space
with blockage and/or haemorrhage in at least one part of the
ventricular system and/or spinal canal. Heterozygous
(Trp53bp2Δ3/+) embryos showed CNS abnormalities, such as
spinal canal stenosis or asymmetric LVs, but with lower
penetrance (Figure 3d). Twenty-five per cent of BALB/c
Trp53bp2Δ3/+ embryos showed localized abnormalities in the
distribution of neuroepithelial brain tissue associated with
small patches of subcranial haemorrhage (Figure 3d).
This shows that ASPP2 is required for early stages of CNS
development. Interestingly, surface rendering of LVs of
Trp53bp2Δ3/Δ3 embryos showed a similar shape to the
dysmorphism observed in patients with TP53BP2 dele-
tion, with bodies of the LVs being more parallel and bulbous
(Figure 3c). This suggests that ASPP2 deficiency in the
Trp53bp2Δ3/Δ3 mice might mimic effects of ASPP2 deficiency in
humans resulting from the heterozygous deletion of TP53BP2.
ASPP2 deficiency causes NTDs in mice. ASPP2 was
reported previously to control the cell polarity and cell
proliferation of neural epithelial cells.10 These are two
important biological processes involved in neural tube closure,
an early event in CNS development, the disruption of which
causes NTDs. To further investigate the effect of genetic back-
ground on phenotype severity in ASPP2-deficient mice, we
compared Trp53bp2Δ3/Δ3 embryos in mixed, B6 and BALB/c
backgrounds. NTDs were detected in 15% (n=127) of
embryos on the mixed background, 46% (n=13) on the pure
B6 background and 8% (n=12) on the BALB/c background
(Figure 4, Supplementary Table 3). The only NTD observed in
BALB/c embryos was exencephaly (Figure 4, Supple-
mentary Figure 4a). On the mixed background, NTDs were
small at the early stages (E9.5−E10.5) but progressed to
larger lesions at 4E13.5, and featured mainly exencephaly
and rostral spina bifida (Figure 4) but rarely craniorachischisis
(Figure 4 − middle panel). In contrast, NTDs in Trp53bp2Δ3/Δ3
B6 embryos have a broad spectrum of phenotypes, ranging
from spina bifida to craniorachischisis with some spina bifida
phenotypes affecting a large section of the neural tube
(Figure 4, Supplementary Figure 4b). MicroCT and HREM
inspection of Trp53bp2Δ3/Δ3 embryos with NTDs revealed
occasional overgrowth of neural tissue (Supplementary
Figure 4a). The spinal column of the neural tube was often
wrinkled, even in embryos without NTDs (Supplementary
Figure 3e).
Given the association of TP53BP2 deletions with brain
structural abnormalities, we wondered whether TP53BP2
deletions might also be associated with NTDs in humans. We
compared the genomic location of human genes orthologous
to genes that have been implicated in NTDs in mice with
chromosomal bands reported by Tyshchenko et al.1 as
associated with NTDs in humans. Interestingly, TP53BP2 is
one of only 16 human genes that lie in these significantly
associated bands (Supplementary Figure 5). Deletions of the
1q41−q44 locus encompassing TP53BP2 are significantly
associated with posterior encephalocele, generally consi-
dered a NTD.1,38,39 This suggests that TP53BP2 deficiency
might also play a role in a subset of human NTDs.
Notably, we found no bias towards females in Trp53bp2Δ3/Δ3
embryos presenting NTDs, whereas NTDs in p53-null mice
occur preferentially in females (Supplementary Figure 4c).14
This suggests that ASPP2 contributes to NTDs via a p53-
independent mechanism. In summary, these results demon-
strate that 100% of Trp53bp2Δ3/Δ3 mice have CNS defects
but their phenotypic characteristics vary substantially with the
genetic background.
Non-CNS phenotypes overlap between Trp53bp2Δ3/Δ3
embryos and 1q41q42 microdeletion syndrome patients.
Visual inspection of Trp53bp2Δ3/Δ3 embryos also revealed
craniofacial and eye abnormalities (Figures 5a and b).
We reported previously that ASPP2-deficient embryos
have highly penetrant retinal abnormalities.10 Some B6
Trp53bp2Δ3/Δ3 embryos lacked one or both eyes (Figure 5a)
while others showed coloboma (incomplete eye tissue)
or microphthalmia (abnormally small eye(s)) (Figure 5b).
We used microCT and HREM to examine Trp53bp2Δ3/Δ3
embryos comprehensively for developmental abnormalities.
At E13.5 and E14.5, 67−100% of B6 and 33−56% of BALB/c
Trp53bp2Δ3/Δ3 embryos had abnormal heart position involving
a 30−45o twist along the coronal axis (Figure 5c), and 67% B6
and 33% BALB/c of Trp53bp2Δ3/Δ3 embryos had ventricular
septal defect (VSD, Figure 5d). Heart function and chamber
Figure 2 Enlarged ventricles and other abnormalities in patients with TP53BP2 deletions. (a) Summary of the patient records analysed in this study. (b) Quantification of
lateral ventricle volume by probabilistic morphometry. Volumes were computed by ALVIN on all suitable scans in each MRI series, from 1q41q42 microdeletion patients with and
without TP53BP2 deletion. Left panel – T1 and T2 sagittal, axial and coronal scans were used for computations of LV volumes, bars showing mean± S.D.; right panel – T1 axial
scans used only, each data point showing the mean from T1 axial scans for each patient. MRI scans of 12 patients and a group of 28 healthy paediatric individuals (NIH controls)
were used. Median age of microdeletion cohort= 19 months, median of NIH controls= 15 months. For statistical comparison of LV volumes in patient groups, values were first
tested for normality by the D’Agostino and Pearson omnibus test, then compared to NIH controls using the two-tailed Student’s t-test and corrected for multiple hypothesis testing
by multiplying the P-value by the number of tests. Mean±S.D. are shown. (c) Axial and sagittal MRI images of brains of 1q41q42 microdeletion patients. T1 non-contrast images
are shown, except for cases where only T2 scans were available (Rosenfeld Subject 14, Spreiz et al.24 and Case 7). Double white arrowheads: hypoplasia of corpus callosum;
single white arrowheads: asymmetry in lateral ventricle size; asterisk: mega cisterna magna
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Figure 3 Trp53bp2Δ3/Δ3 and Trp53bp2Δ3/+ mice have CNS defects. (a) Gross dilation of lateral ventricles is visible in Trp53bp2Δ3/Δ3 embryos, resulting in bulging foreheads.
Intraventricular haemorrhage is frequently seen (white arrows). (b) Present and absent pineal gland (red arrows) in wild-type and Trp53bp2Δ3/Δ3 embryos, respectively, as seen in
a single HREM section. (c) Surface rendering of lateral ventricles in 1q41q42 microdeletion patients (left, constructed from MRI scans) and Trp53bp2Δ3/Δ3 vs wild-type embryos
(right, constructed from microCT scans). (d) Brain abnormalities in heterozygous Trp53bp2Δ3/+ embryos. Left: Asymmetry of lateral ventricles in a heterozygous Trp53bp2Δ3/+
embryo caused by a structural abnormality (red arrow). MicroCT image is shown. Right: Asymmetry in neuroepithelial tissue distribution in the brain (red arrow) and the
associated subcranial haemorrhage (white and red arrows) in a BALB/c Trp53bp2Δ3/+ embryo
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volumes of adult BALB/c Trp53bp2Δ3/Δ3 mice were normal
(Supplementary Figure 6a). Trp53bp2Δ3/Δ3 embryos in B6 and
mixed backgrounds showed various craniofacial abnormal-
ities including dolichocephaly (an elongation of the head),
micrognathia (smaller lower jaw) (Figures 5a and 6) and cleft
palate (Figure 5e). A high percentage of embryos also showed
gonadal abnormalities resulting in unclear gender at E14.5
(Figure 5f), urethral abnormalities (Figure 5g), abnormal
trigeminal nerve and spinal ganglia (Supplementary Figure
6b and c), and multiple other defects of varying penetrance
(Figure 6). Notably, 33% of BALB/c Trp53bp2Δ3/Δ3 embryos
lacked a visible abducens nerve.
Embryoswith heterozygous deletion of exon 3 (Trp53bp2Δ3/+)
examined by microCT had 30% incidence of cleft palate in the
B6 background, and 30% and 13% incidence of VSD in B6
and BALB/c backgrounds, respectively. While this manu-
script was in preparation, the International Mouse Pheno-
typing Consortium (IMPC, www.mousephenotype.org) –
who are performing broad phenotyping for 20 000 mouse
genes (3154 to date) − released phenotypic data on mice
with a Trp53bp2−exon4− deletion genotype, termed
Trp53bp2tm1b(EUCOMM)Hmgu.40 Our analysis of this publicly
available data showed that this homozygous deletion of
Trp53bp2 exon 4 (Trp53bp2Δ4/Δ4) is lethal, with 100%
penetrance prior to embryonic day 9 (Supplementary
Figure 7a). Trp53bp2Δ4/+ mice were viable and males showed
a significant hyperactive phenotype in the open-field test
(Supplementary Figure 7b). The Trp53bp2Δ4/+ males showed
no difference in the percentage of time spent in the centre of
the open field, indicating the phenotype is highly specific to
locomotor activation (Supplementary Figure 7b). Of note,
these mice also showed lower grip strength normalized by
body weight, short tibia, higher bone density, and an abnormal
glucose response (Supplementary Figures 7c-e). These data
from the heterozygotes demonstrate that ASPP2 is haploin-
sufficient in mouse development.
There is substantial overlap in the phenotypic spectrum –
including brain, neurological, craniofacial, eye, heart, and
urogenital defects − of ASPP2-deficient mice and patients
with deletions involving 1q41q42. Fifty per cent of patients with
TP53BP2 deletion had cleft palate, which was observed in
33% and 67% of BALB/c and B6 Trp53bp2Δ3/Δ3 embryos,
respectively. Heart abnormalities, including VSD, were
reported for 31% of patients with TP53BP2 deletion, and
30% of B6 Trp53bp2Δ3/+ embryos had VSD. 1q41q42
microdeletion patients also frequently present with hypotonia
and hypoglycaemia with hypoglycaemic seizures, represent-
ing phenotypic overlap with the reduced grip strength
and abnormalities in glucose response in Trp53bp2Δ4/+ mice
(see above). Overall, the relative penetrance of defects in
Trp53bp2Δ3/Δ3 embryos also broadly correspond to the
frequency of their occurrence in 1q41q42 deletion patients:
virtually all diagnosed cases with 1q41q42 deletions have
intellectual disability and/or brain structural abnormalities
and there is high penetrance of CNS abnormalities in
Trp53bp2Δ3/Δ3 mice, with lower proportions of 1q41q42
deletion patients and Trp53bp2Δ3/Δ3 mice having the other
phenotypes. These results suggest that TP53BP2 haploin-
sufficiency might be implicated in additional abnormalities
associated with the 1q41q42 microdeletion syndrome and
1q41q42 deletions more generally.
Discussion
Chromosomal deletion-associated human disorders often
have variable phenotypes and severity among individuals,
and the vast majority of pathogenic deletions include multiple
genes, hampering the identification of causal genes.
Figure 4 Trp53bp2Δ3/Δ3 mice have neural tube defects. Strain dependence of NTD penetrance in Trp53bp2Δ3/Δ3 mice: Embryo phenotypes in pure C57BL/6 (left), mixed
129 Sv-C57BL/6 (middle), and BALB/c (right) background embryos range in severity from small exencephaly (right, white arrow) to severe craniorachischisis (left upper panel,
white arrows). Spina bifida is also observed in the mixed (middle panels, white arrows) and B6 (left lower panel, white arrow) backgrounds
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Experimental model systems are, therefore, needed to aid the
identification of causal genes in human developmental
disorders. Here we have identified TP53BP2 as a candidate
gene responsible for brain abnormalities in 1q41q42 micro-
deletion syndrome and show that ASPP2-deficient mice also
develop CNS abnormalities with 100% penetrance, with
Figure 5 ASPP2-deficient mice have non-CNS phenotypes. (a) Craniofacial abnormalities in Trp53bp2Δ3/Δ3 E14.5 embryos include dolichocephaly and hypoplasia or
agenesis of the lower jaw (white arrows). (b) Eye abnormalities observed in Trp53bp2Δ3/Δ3 mice feature coloboma (top, missing tissue indicated by red arrow) and microphthalmia
(bottom) in E14.5 embryos. (c) Abnormal heart position is seen in all B6 embryos examined. The microCT-based 3D reconstruction shows the heart is twisted approximately 45°
along the coronal axis (top panel), sometimes resulting in an altered direction of the ductus arteriosus with respect to the aorta (axial view, white arrow). Colour coding: yellow –
right ventricle; pink – left ventricle; blue – trachea; red – aorta; light green – ductus arteriosus. (d) Ventricular septal defect in Trp53bp2Δ3/Δ3 E14.5 embryonic heart (red arrow),
shown on a representative HREM section. (e) Palate (red arrows) showing cleft palate in Trp53bp2Δ3/Δ3 E14.5 embryo. (f) Largest-area HREM section of gonads (red arrows)
showing abnormalities and unclear gender in a Trp53bp2Δ3/Δ3 E14.5 embryo versus male E14.5 wild-type embryo. (g) Single versus double ureter (red arrows) in wild-type
versus Trp53bp2Δ3/Δ3 E14.5 embryos, respectively, as visible by HREM
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phenotypic differences depending on background. Notably,
TP53BP2 is the only gene in the critical region for brain
abnormalities of the syndrome for which the gene-deficient
mouse model has a CNS phenotype.
Recently, a 1q41q42 microdeletion case with brain abnorm-
alities was reported whose deletion included the last exon of
FBXO28, suggesting that FBXO28 might also be responsible
for these abnormalities.41 A mouse deficient in FBXO28
is currently unavailable. Importantly, Case 6 in our report
(Figure 1, Supplementary Table 1) showed occipital encepha-
locele, yet harbours a deletion that includes TP53BP2 but
excludes FBXO28. FBXO28 lies outside the existing SRO for
brain abnormalities, but it is possible that there are multiple
dosage-sensitive genes for brain development in the 1q41q42
region and future studies are needed to investigate this. For
example, patients with non-overlapping DISP1 and FBXO28
deletions both showed seizures,4,42 despite the fact that
DISP1 is not contained in the critical region of the syndrome.
Few mouse models exist that are deficient in human 1q4-
located genes and phenocopy the abnormalities associated
with 1q4 deletions to a significant extent. The ASPP2-deficient
mice described here show craniofacial, eye, heart and
urogenital abnormalities in addition to CNS defects, all of which
are associated with 1q41q42 deletions. Interestingly, among
the 31% of patients with TP53BP2 deletions who presented
with eye abnormalities, strabismus and optic nerve hypoplasia
were common. Our HREM analysis of Trp53bp2Δ3/Δ3 embryos
revealed hypoplastic or absent optic nerve and abducens nerve
among 33% and 67% of B6 and BALB/c embryos, respectively.
Given that the abducens nerve controls eyemovement through
the lateral rectus muscle, it would be interesting to test whether
patients with strabismus and TP53BP2 deletions have any
abducens nerve abnormalities. We note that our ability to
determine penetrance precisely is limited by the low number of
Trp53bp2Δ3/Δ3 embryos (n=3) on the BALB/c background
analysed by HREM, due to the demanding nature of this
technique. Overall, these observations might explain the
significant phenotypic heterogeneity associated with 1q41q42
deletions: there are likely multiple dosage-sensitive genes in
the region whose haploinsufficiency is both incompletely
penetrant and variably expressed. The observation of NTDs
in some of the ASPP2-deficient mice suggests that it would
Figure 6 Summary of phenotypes in Trp53bp2Δ3/Δ3 and Trp53bp2Δ3/+ embryos. Abnormalities detected by naked eye (visual inspection), microCT, and HREM in E13.5 and
E14.5 ASPP2-deficient embryos. Frequency and the number of embryos evaluated for each phenotype are given. Wild-type littermate embryos were used as reference controls.
In the case of BALB/c embryos, eye abnormalities were difficult to determine visually and were therefore quantified for a small number of embryos
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be informative to investigate whether mutations involving
TP53BP2 might contribute to NTDs in humans.
To date, three different Trp53bp2-deficient mouse lines have
been generated: exon 3 deletion mice reported by our group
(Trp53bp2Δ3/Δ3),9 exon 4 deletion mice generated by the
International Knockout Mouse Consortium (IKMC)
(Trp53bp2Δ4/Δ4),43 and mice with deletion of exons 10− 17
(Trp53bp2Δ10− 17/Δ10− 17).8 Homozygous deletion of exon 4 or
exons 10−17 is lethal prior to embryonic day 9 with 100%
penetrance, whereas deletion of exon 3 results in neonatal
lethality with background-dependent penetrance. The exon 3
deletion is an in-frame deletion causing only the major isoform
of Trp53bp2 to be deleted completely; low levels of shorter
forms of Trp53bp2 can be expressed. Therefore Trp53bp2Δ3
acts as a hypomorphic allele, which has allowed us to discover
developmental effects of ASPP2 deficiency that could not be
observed with full-knockout alleles due to their early embryo-
nic lethality.
Imaging of heterozygous Trp53bp2Δ3/+ embryos showed a
lower frequency of structural abnormalities than observed in
patients with heterozygous TP53BP2 deletions. One possible
explanation is that the exon 3 deletion is a hypomorphic allele,
compared to the complete deletion allele in the patients. In
addition, more than one gene is deleted in each 1q41q42
microdeletion. Therefore, the concomitant deletion of multiple
haploinsufficient genes might exacerbate the phenotype,
as is the case in other known contiguous gene deletion
syndromes.44,45
At the protein level, the ability of ASPP2 to regulate
apicobasal polarity and p53-dependent apoptosis is likely
important for its role in neural tube closure. Recently,
inappropriate activation of p53 during development was linked
with the pathogenesis of CHARGE syndrome, a disorder
characterized by abnormalities including developmental delay,
heart defects, coloboma, cranial nerve abnormalities, choanal
atresia, and inner ear abnormalities.44,45 The phenotypic
spectrum in the CHARGE syndrome mouse model shows
substantial overlap with the ASPP2-deficient mice (including
NTDs, short lower jaw, coloboma, and heart defects),
suggesting that dysregulated p53 activity might be responsible
for these phenotypes in ASPP2-deficient mice. However,
while p53-deficient and p53-overactivated embryos show
primarily exencephaly,14,44 ASPP2-deficient embryos develop
mainly spina bifida or craniorachischisis, pointing to the
importance of p53-independent functions of ASPP2.
ASPP2 is also an important regulator of epithelial plasticity
and apicobasal polarity.10,46 Recent studies of Grainyhead-
like 2 mutants have shown that dysregulated epithelial-to-
mesenchymal transition can cause NTDs.47 It is possible that
loss of epithelial character together with the loss of apicobasal
polarity disrupts neural tube closure in ASPP2-deficient
embryos. ASPP2-deficient embryos also showed overgrowth
of neural tissue both in the brain and in the spinal cord. The
surplus of neuroepithelial cells might also contribute to NTDs
and potentially other CNS phenotypes in these embryos
through mechanical obstruction. Regardless of the exact
cellular mechanism, the observed phenotypical similarities
between ASPP2 deficiency in mice and humans highlight the
importance of ASPP2 in controlling CNS development in both
mice and humans.
Materials and Methods
Patient recruitment. Patients with 1q4 deletions were enrolled and
de-identified data collected following the UK NHS Research Ethics Committee
approval (09/H0606/78, Amendment 3), and in accordance with the Institutional
Review Board protocols of the participating institutions.
Comparative genomic hybridization. DNA isolated from patients’ blood
were analysed by chromosomal microarray following the participating institutions’
standard protocols. With the exception of Case 7, all new 1q microdeletion cases
have been deposited on the DECIPHER database (https://decipher.sanger.ac.uk/).
Brain MRI and morphometry. De-identified brain MRI and/or CT scans
were obtained in DICOM format from radiology departments where the scans were
recorded. Normal MRI controls used in the preparation of this article were obtained
from the Pediatric MRI Data Repository created by the NIH MRI Study of Normal
Brain Development. To quantify LV volume, MRI scans were first converted to Nifti
format using MRIConvert (University of Oregon, USA; http://lcni.uoregon.edu/
downloads/mriconvert) and subsequently analysed by ALVIN.48 Multiple scans in
each series were used to compute LV volume to produce Figure 2b − left. Axial T1
scans only were used to compute LV volumes for genotype comparison as shown in
Figure 2b − right. Out of the fourteen 1q41q42 microdeletion MRI scans, two
patient scans (Rosenfeld 9 and Case 7) were unsuitable for morphometry: Case 7 is
a prenatal case and the scan for Rosenfeld 9 cannot be converted into Nifti.
Therefore, the morphometric analysis of LV volume was performed with 12 patient
scans. More information on the NIH cohort is given in Acknowledgments.
Mice. Experiments with mice received UK Home Office approval, Project licence
number 30/2862 and fully complied with the UK Home Office guidelines. For this
study, Trp53bp2Δ3 mice in a pure C57BL/6J, mixed C57BL/6Jx129SvJ, and pure
BALB/c backgrounds were crossed to generate wild-type, Trp53bp2Δ3/+, and
Trp53bp2Δ3/Δ3 embryos.10 Pregnant females were killed at the indicated time points
during pregnancy and embryos were collected and genotyped using the following
primers: 5′-CTCCACCCCAGGAAATTACA-3′ (intron 3), 5′-CGGTTTGGAAGTCAA
AGGAA-3′ (exon 3), and 5′-GGACCGCTATCAGGACATA-3′ (neomycin resistance
gene).
Embryo sexing. The following primers for ZFY were used for sexing by PCR:
5′-GACTAGACATGTCTTAACATCTGTCC-3′ and 5′-CCTATTGCATGGACAGCA
GCTTATG-3′. The following GADPH primers were used as controls for the PCR
reaction: 5′-TGGCTACAGTAACCGAGTGGT-3′ and 5′-CTTTGAGTGGAAGCCGA
AGT-3′.
Mouse micro-computed tomography. Embryos generated from mice as
described above were first killed on ice-cold PBS, washed in phenol red-free Hank’s
salts with EDTA, removed from their yolk sac, their umbilical cord cut, and the freed
embryo fixed in 4% formaldehyde for at least 24 h. Each embryo was then
immersed in 2 ml Lugol solution (L6146, Sigma-Aldrich, St Louis, MO, USA) for 72 h
at 4 °C. All incubations included the replacement of staining solution after the first
24 h. Four embryos were embedded in 1% agarose (Web Scientific, Crewe, UK) in
a dedicated sample holder and scanned using a micro-CT scanner (SkyScan
1172, Bruker, Kontich, Belgium) at a nominal isotropic pixel size of 4.9 μm (scan
parameters: X-ray source voltage – 48 kV; current – 208 mA; filter – a 0.5 mm Al
filter; number of projections – 900). The total scan time was 8 h for four embryos.
The images' projections were reconstructed with the scanner-built-in reconstruc-
tion software ‘NRecon’ and downsampled offline by a factor of 2, resulting in a
9.8 μm isotropic voxel size. Image analysis (i.e. 3D segmentation and rendering) was
performed in Amira (FEI Ltd, Hillsboro, OR, USA).
High-resolution episcopic microscopy. HREM images of E14.5
embryos were obtained as previously described.37 We used the episcopic proce-
dures for sectioning and image capture using a previously described arrangement of
microtome and magnification optic.49
Mouse echocardiography. Adult female Balb/c Trp53bp2Δ3/Δ3 mice (n= 8)
and age-matched wild-type controls (n= 7) received echocardiographic examination
at a mean age of 28 weeks. Mice were lightly anaesthetized using 1− 1.5%
isoflurane in 100% medical oxygen, kept warm on a homeothermic blanket, and
imaged using a VisualSonics Vevo 2100 (Toronto, Canada) with 22− 55 MHz
transducer. B-mode trans-thoracic short-axis and long-axis images were obtained to
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assess left ventricular volumes and function, and pulmonary artery Doppler flow as
a measure of right-sided function. Images were obtained and analysed using Vevo
2100 v1.6.0 software by a single operator blinded to genotype.
Trp53bp2 exon 4 deletion mice (Trp53bp2Δ4). Publicly available
phenotypic data for Trp53bp2Δ4/Δ4 and Trp53bp2Δ4/+ mice were mined from
the International Mouse Phenotype Consortium (IMPC) URL (https://www.
mousephenotype.org/data/genes/MGI:2138319) release 4.3, last updated 12 May
2016, and from Phenoview (https://www.mousephenotype.org/phenoview), updated
18 May 2016. Raw data were re-plotted using Graphpad Prism version 6.05
for Windows (GraphPad Software, La Jolla, CA, USA). Experimental design by
IMPC followed the protocols of the International Mouse Phenotyping Resource of
Standardized Screens (https://www.mousephenotype.org/impress). For statistical
testing, results from IMPC’s Mixed Model framework, linear mixed-effects model,
were adopted. P values below 0.05 were deemed significant.
Visualization and statistical analysis. Data for panels in Figures 1a and
c were generated using the UCSC Genome Browser (http://genome.ucsc.edu/),50
genome release hg19. Plots in panels Figures 1b and 2b, Supplementary Figure 1b,
and Supplementary Figures 7a-d were generated using Graphpad Prism version
6.05 for Windows (GraphPad Software, La Jolla, CA, USA). Chromosome plots in
Supplementary Figure 5 were generated using Phenogram (http://visualization.
ritchielab.psu.edu/phenograms/plot).51 Statistical tests were performed in Graphpad
Prism (see above) and R.52
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